Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-hyperactivity medication: methylphenidate and amphetamine

P Seeman1, B K Madras

  • 1Department of Pharmacology, University of Toronto, Canada.

Molecular Psychiatry
|October 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients.

Scientific reports·2021
Same author

Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations.

European journal of neurology·2020
Same author

THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Drug and alcohol dependence·2020
Same author

Novel SBF2 mutations and clinical spectrum of Charcot-Marie-Tooth neuropathy type 4B2.

Clinical genetics·2018
Same author

Charcot-Marie-Tooth 1A: Heterozygous T118M Mutation over a CMT1A Duplication Has No Influence on the Phenotype.

Annals of the New York Academy of Sciences·2017
Same author

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.

Translational psychiatry·2016
Same journal

Diagnostic and sex effects on frontostriatal brain wiring structural organization in early psychosis affective subjects compared to healthy controls.

Molecular psychiatry·2026
Same journal

Effects of family genetic risk scores and environmental factors on risk of schizophrenia and bipolar disorder.

Molecular psychiatry·2026
Same journal

Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.

Molecular psychiatry·2026
Same journal

Copy number variant scores are associated with cerebrovascular pathology in aging.

Molecular psychiatry·2026
Same journal

Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.

Molecular psychiatry·2026
Same journal

Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

Molecular psychiatry·2026
See all related articles

Stimulant medications paradoxically reduce hyperactivity in ADHD by affecting dopamine levels. This review explores how raising dopamine can lead to psychomotor slowing in hyperactive individuals.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Child Psychology

Background:

  • Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by hyperactivity and impulsivity.
  • Stimulant medications are a primary treatment for ADHD, but their mechanism of action, particularly regarding dopamine, presents apparent paradoxes.
  • Dopamine is known to enhance motor activity, yet stimulants that increase extracellular dopamine can reduce hyperactivity.

Purpose of the Study:

  • To review the mechanism of action of stimulant medications in treating hyperactivity in children and adults with ADHD.
  • To address the paradox of how dopamine-raising drugs can cause psychomotor slowing in hyperactive individuals.
  • To elucidate the complex role of dopamine in ADHD and stimulant response.

Main Methods:

Related Experiment Videos

  • Literature review of existing studies on stimulant pharmacology and ADHD.
  • Analysis of the neurobiological effects of stimulants on dopamine pathways.
  • Examination of clinical observations regarding psychomotor activity in response to stimulants.

Main Results:

  • Stimulants increase extracellular dopamine, particularly in the prefrontal cortex, which is implicated in executive functions.
  • The paradoxical psychomotor slowing is hypothesized to result from normalization of dopamine levels in specific brain circuits, rather than a general increase.
  • Dopamine's role in ADHD is complex, involving dysregulation in multiple neurotransmitter systems and brain regions.

Conclusions:

  • Stimulant medications alleviate ADHD symptoms by modulating dopamine neurotransmission, despite the apparent paradox of psychomotor slowing.
  • Understanding these mechanisms is crucial for optimizing ADHD treatment and managing patient response.
  • Further research is needed to fully unravel the intricate neurobiology of ADHD and stimulant action.